|

KarX-EC Clinical Trials

4 actively recruiting trials across 4 locations

No change since May 2026

Also known as: BMS-986519, Xanomeline Enteric-coated, Xanomeline enteric capsules, BMS-986519

Pipeline

Phase 3: 4

Top Sponsors

  • Bristol-Myers Squibb4

Indications

Chandler, Arizona1 trial

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Local Institution - 2609

Phase 3

Gilbert, Arizona1 trial

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Local Institution - 0042

Phase 3

Fullerton, California1 trial

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Fullerton Neurology and Headache Center

Phase 3

Long Beach, California1 trial

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Healthy Brain Clinic

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.